Arcutis’s ZORYVE Upswing: A 2025 Run-Up, With a 2026 Revenue Forecast in Focus

Executive snapshot: a product-led growth story with cash-flow vibes

Arcutis Biotherapeutics, Inc. (ARQT) delivered a results package that reads like a dermatology playbook tuned for scale. ZORYVE (roflumilast) is the star, and Q4 2025 net product revenue for ZORYVE was $127.5 million, up 84% year over year and 29% sequential from Q3 2025. For the full year 2025, ZORYVE net product revenue reached $372.1 million, a 123% leap versus 2024. In the same breath, the company reports positive operating cash flow in Q4 2025 and projects ongoing quarterly positive cash flow going forward.

Growth details that matter

• Revenue forecast cue: 2026 full-year net product sales guidance raised to $480–$495 million, signaling management confidence in continued demand and pricing trajectory for ZORYVE.
• Strategic expansion: the company is expanding its dermatology sales force and separately kicking off a targeted Arcutis commercialization effort for primary care and pediatric health care providers, a move designed to broaden prescriber access beyond dermatology specialists.
• Product expansion: ZORYVE cream 0.05% was launched for children aged 2 to 5 years following FDA approval in October 2025, opening a new patient segment and potential tailwinds for sales growth.
• Market access: Medicare access began in January 2026, with about one in three Medicare patients now having non-preferred access to ZORYVE—an important payer dynamic that could shape formulary positioning and GTN (gross-to-net) trends in 2026 and beyond.
• Operational momentum: the company reported positive operating cash flow in Q4 2025 and signaled the intention to maintain positive quarterly OCF going forward, reinforcing the balance between growth investments and cash generation.
• Portfolio economics: the release emphasizes net product revenue rather than earnings per share (EPS) figures, leaving EPS consensus and earnings surprise metrics to be inferred from future quarterly results and margin progress.
• Commercial reshaping: termination of the promotion agreement with Kowa in January 2026 is noted, with Arcutis indicating it will assume certain resourced responsibilities—an implicit reallocation of promotional efforts and costs as the company scales.

What this portends for Arcutis and its sector peers

The combination of a fast-growing product (ZORYVE), a clear 2026 revenue trajectory, and payer-access dynamics suggests a multi-year runway rather than a one-off spike. For ARQT, the 2026 guidance implies that sales growth can be sustained even as the company invests in expanded sales coverage and a broader commercial push. If ZORYVE maintains its 2025 momentum—driven by robust demand, improved GTN economics, and payer access gains—the company could approach or exceed mid-to-high single-digit operating margins by year-end, assuming R&D and SG&A intensity does not flip the math.

For sector peers in immuno-dermatology and specialty pharma, a few takeaways emerge:

• Payer strategy matters: Medicare access improvements and formulary positioning can be as consequential as clinical milestones. Companies that pair product launches with payer access wins may see more durable top-line growth and cleaner cash-flow paths.
• Patient-access expansion drives revenue mix: broadening into pediatrics and primary care expands the addressable population, potentially increasing run-rate revenue even when base prices stabilize or modestly compress.
• Cash efficiency matters: Arcutis’ focus on positive operating cash flow, even as it grows, signals that balance-sheet discipline isn’t being sacrificed for speed. Translating revenue gains into free cash flow remains the true test for sustainable, capital-efficient growth.
• Operational restructuring carries risk and opportunity: terminating a promotional agreement with a collaborator (Kowa) can shift cost structures and channel dynamics. Sector peers may watch closely to see whether this kind of repositioning unlocks greater control—and margin upside—or introduces execution risk during the transition.

Risks and uncertainties to watch

The forward-looking statements hinge on several variables: whether ZORYVE sustains its growing trajectory, payer access evolves in a favorable manner for the broader patient base, and the company can convert increased prescriber reach into durable gross margin expansion. The absence of a disclosed EPS figure or EPS consensus in the release means investors will be watching upcoming quarterly results for a more granular view of profitability and margin progression. The sNDA timing for new indications and the ultimate impact of the Kowa termination on commercial leverage remain meaningful catalysts to validate the growth narrative.

Closing thought: a creamsicle of opportunity, if the price is right

The Arcutis narrative in 2025 reads like a well-timed mix of clinical momentum, payer navigation, and disciplined capital discipline. ZORYVE’s top-line story is credible and actionable, and the 2026 revenue forecast points to a growth runway that could attract interest from peers and capital markets alike. Whether this translates into sustained EPS momentum will depend on how well the company translates sales growth into margin expansion and how effectively it manages commercialization costs during the broader market rollout. In short, the data hints at a durable, product-driven ascent—one that may force a few sector peers to reconsider their own go-to-market playbooks.